Skip to main content
Erschienen in: International Journal of Clinical Oncology 3/2014

01.06.2014 | Original Article

Predictive factors that influence the course of medullary thyroid carcinoma

verfasst von: Kalliopi Pazaitou-Panayiotou, Alexandra Chrisoulidou, Stylianos Mandanas, Konstantinos Tziomalos, Eleni Doumala, Frideriki Patakiouta

Erschienen in: International Journal of Clinical Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Medullary thyroid cancer (MTC) is an infrequent form of thyroid cancer. We aimed to examine how gender and histological characteristics influence the rate of recurrence/persistent disease, distant metastases and survival and also to define specific characteristics of MTC microcarcinomas.

Methods

The medical records of 85 patients with MTC were reviewed. The following characteristics were recorded: year of diagnosis, age at diagnosis, sex, tumor size, number of tumor foci, lymph node metastases, thyroid capsule and vascular invasion, infiltration of thyroid parenchyma and extrathyroid extension, and distant metastases.

Results

During follow-up (mean 78.8 months), persistent disease occurred in 40 patients, local recurrences in 5 and distant metastases in 32 patients. Local and distant disease appeared more frequently in patients with larger tumors (p < 0.005) and lymph node metastases (p < 0.01). In addition, patients with invasive tumors had local and distant disease more frequently. The percentage of males who had persistent disease and/or local recurrence was significantly higher than the percentage of males who did not (p < 0.05). Similar results were observed for distant disease (p < 0.01). Independent predictors of recurrence and persistent disease was the presence of lymph node metastases at diagnosis (risk ratio 11.66) and of distant metastases were the presence of lymph node metastases at diagnosis (risk ratio 17.42) and the presence of vascular invasion (risk ratio 2.41). Fifteen patients died due to MTC during follow-up (17.6 %). Patients who died were more frequently males, and had thyroid capsule invasion, extrathyroidal extension, vascular invasion and metastatic disease.

Conclusions

Male sex, tumor size and invasive characteristics of the tumor are negative predictive factors for evolution of MTC.
Literatur
1.
Zurück zum Zitat Pacini F, Castagna MG, Cipri C et al (2010) Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) 22:475–485CrossRef Pacini F, Castagna MG, Cipri C et al (2010) Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) 22:475–485CrossRef
2.
Zurück zum Zitat Pelizzo MR, Boschin IM, Bernante P et al (2007) Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 33:493–497PubMedCrossRef Pelizzo MR, Boschin IM, Bernante P et al (2007) Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 33:493–497PubMedCrossRef
3.
Zurück zum Zitat Grozinsky-Glasberg S, Benbassat CA, Tsvetov G et al (2007) Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005. Thyroid 17:549–556PubMedCrossRef Grozinsky-Glasberg S, Benbassat CA, Tsvetov G et al (2007) Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005. Thyroid 17:549–556PubMedCrossRef
4.
Zurück zum Zitat Elisei R, Bottici V, Luchetti F et al (2004) Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 89:163–168PubMedCrossRef Elisei R, Bottici V, Luchetti F et al (2004) Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 89:163–168PubMedCrossRef
5.
Zurück zum Zitat Abraham DT, Low TH, Messina M et al (2011) Medullary thyroid carcinoma: long-term outcomes of surgical treatment. Ann Surg Oncol 18:219–225PubMedCrossRef Abraham DT, Low TH, Messina M et al (2011) Medullary thyroid carcinoma: long-term outcomes of surgical treatment. Ann Surg Oncol 18:219–225PubMedCrossRef
6.
Zurück zum Zitat Cupisti K, Wolf A, Raffel A et al (2007) Long-term clinical and biochemical followup in medullary thyroid carcinoma: a single institution’s experience over 20 years. Ann Surg 246:815–821PubMedCrossRef Cupisti K, Wolf A, Raffel A et al (2007) Long-term clinical and biochemical followup in medullary thyroid carcinoma: a single institution’s experience over 20 years. Ann Surg 246:815–821PubMedCrossRef
7.
Zurück zum Zitat de Groot JW, Plukker JT, Wolffenbuttel BH et al (2006) Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol (Oxf) 65:729–736CrossRef de Groot JW, Plukker JT, Wolffenbuttel BH et al (2006) Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol (Oxf) 65:729–736CrossRef
8.
Zurück zum Zitat Kandil E, Gilson MM, Alabbas HH et al (2011) Survival implications of cervical lymphadenectomy in patients with medullary thyroid cancer. Ann Surg Oncol 18:1028–1034PubMedCrossRef Kandil E, Gilson MM, Alabbas HH et al (2011) Survival implications of cervical lymphadenectomy in patients with medullary thyroid cancer. Ann Surg Oncol 18:1028–1034PubMedCrossRef
9.
Zurück zum Zitat Gulben K, Berberoglu U, Boyabatli M (2006) Prognostic factors for sporadic medullary thyroid carcinoma. World J Surg 30:84–90PubMedCrossRef Gulben K, Berberoglu U, Boyabatli M (2006) Prognostic factors for sporadic medullary thyroid carcinoma. World J Surg 30:84–90PubMedCrossRef
10.
Zurück zum Zitat Schlumberger M, Carlomagno F, Baudin E et al (2008) New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 4:22–32PubMedCrossRef Schlumberger M, Carlomagno F, Baudin E et al (2008) New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 4:22–32PubMedCrossRef
11.
Zurück zum Zitat Machens A, Dralle H (2012) Biological relevance of medullary thyroid microcarcinoma. J Clin Endocrinol Metab 97:1547–1553PubMedCrossRef Machens A, Dralle H (2012) Biological relevance of medullary thyroid microcarcinoma. J Clin Endocrinol Metab 97:1547–1553PubMedCrossRef
12.
Zurück zum Zitat Kloos RT, Eng C, Evans DB et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565–612PubMedCrossRef Kloos RT, Eng C, Evans DB et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565–612PubMedCrossRef
13.
Zurück zum Zitat Sobin LH, Gospodarowicz M, Wittekind C et al (2010) UICC: TNM classification of malignant tumors, 7th edn. Wiley-Blackwell, New York Sobin LH, Gospodarowicz M, Wittekind C et al (2010) UICC: TNM classification of malignant tumors, 7th edn. Wiley-Blackwell, New York
14.
Zurück zum Zitat Kazaure HS, Roman SA, Sosa JA (2012) Medullary thyroid microcarcinoma: a population-level analysis of 310 patients. Cancer 118:620–627PubMedCrossRef Kazaure HS, Roman SA, Sosa JA (2012) Medullary thyroid microcarcinoma: a population-level analysis of 310 patients. Cancer 118:620–627PubMedCrossRef
15.
Zurück zum Zitat Wells SA Jr, Robinson BG, Gagel RF et al (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30:134–141PubMedCentralPubMedCrossRef Wells SA Jr, Robinson BG, Gagel RF et al (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30:134–141PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Almeida MQ, Hoff AO (2012) Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma. Curr Opin Oncol 24:229–234PubMedCrossRef Almeida MQ, Hoff AO (2012) Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma. Curr Opin Oncol 24:229–234PubMedCrossRef
17.
Zurück zum Zitat Druce M, Chung TT, Grozinsky-Glasberg S et al (2012) Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma. Clin Endocrinol (Oxf) 77:154–155CrossRef Druce M, Chung TT, Grozinsky-Glasberg S et al (2012) Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma. Clin Endocrinol (Oxf) 77:154–155CrossRef
18.
Zurück zum Zitat Vierhapper H, Niederle B, Bieglmayer C et al (2005) Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid 15:1267–1272PubMedCrossRef Vierhapper H, Niederle B, Bieglmayer C et al (2005) Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid 15:1267–1272PubMedCrossRef
19.
Zurück zum Zitat Machens A, Gimm O, Ukkat J et al (2000) Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer 88:1909–1915PubMedCrossRef Machens A, Gimm O, Ukkat J et al (2000) Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer 88:1909–1915PubMedCrossRef
20.
Zurück zum Zitat Kebebew E, Ituarte PH, Siperstein AE et al (2000) Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88:1139–1148PubMedCrossRef Kebebew E, Ituarte PH, Siperstein AE et al (2000) Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88:1139–1148PubMedCrossRef
21.
Zurück zum Zitat Modigliani E, Cohen R, Campos JM et al (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) 48:265–273CrossRef Modigliani E, Cohen R, Campos JM et al (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) 48:265–273CrossRef
22.
Zurück zum Zitat Ismailov SI, Piulatova NR (2004) Postoperative calcitonin study in medullary thyroid carcinoma. Endocr Relat Cancer 11:357–363PubMedCrossRef Ismailov SI, Piulatova NR (2004) Postoperative calcitonin study in medullary thyroid carcinoma. Endocr Relat Cancer 11:357–363PubMedCrossRef
23.
Zurück zum Zitat Clark JR, Fridman TR, Odell MJ et al (2005) Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope 115:1445–1450PubMedCrossRef Clark JR, Fridman TR, Odell MJ et al (2005) Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope 115:1445–1450PubMedCrossRef
24.
Zurück zum Zitat Lorenz K, Brauckhoff M, Behrmann C et al (2005) Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery 138:986–993PubMedCrossRef Lorenz K, Brauckhoff M, Behrmann C et al (2005) Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery 138:986–993PubMedCrossRef
25.
Zurück zum Zitat Saad MF, Ordonez NG, Rashid RK et al (1984) Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 63:319–342CrossRef Saad MF, Ordonez NG, Rashid RK et al (1984) Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 63:319–342CrossRef
26.
Zurück zum Zitat Scopsi L, Sampietro G, Boracchi P et al (1996) Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients. Cancer 78:2173–2183PubMedCrossRef Scopsi L, Sampietro G, Boracchi P et al (1996) Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients. Cancer 78:2173–2183PubMedCrossRef
27.
Zurück zum Zitat Machens A, Hauptmann S, Dralle H (2006) Disparities between male and female patients with thyroid cancers: sex difference or gender divide? Clin Endocrinol (Oxf) 65:500–505CrossRef Machens A, Hauptmann S, Dralle H (2006) Disparities between male and female patients with thyroid cancers: sex difference or gender divide? Clin Endocrinol (Oxf) 65:500–505CrossRef
Metadaten
Titel
Predictive factors that influence the course of medullary thyroid carcinoma
verfasst von
Kalliopi Pazaitou-Panayiotou
Alexandra Chrisoulidou
Stylianos Mandanas
Konstantinos Tziomalos
Eleni Doumala
Frideriki Patakiouta
Publikationsdatum
01.06.2014
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 3/2014
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-013-0588-8

Weitere Artikel der Ausgabe 3/2014

International Journal of Clinical Oncology 3/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.